When IXICO was first founded, the company name came from a description of its original focus ‘Information extraction from Images’. As our technology offering developed we evolved our platform to a cloud-based AI-driven biomarker analytics engine.
Today, we are proud to introduce a new name for that technology platform: IXI™. Keeping things simple and clear, but also making a strong statement that our technology is at the heart of everything we do.
This is much more than a simple rebrand. It reflects how far the Platform has evolved. And the plans we have for the future of IXI™.
Diag 1. IXI™- Regulatory compliant data management platform
When the Platform was first developed, its primary purpose was already then to deliver AI-driven biomarker insights. Being somewhat ahead of its time, especially in the neurology market where precision medicine was slowly making its entrance, the company decided to focus on supporting the operational management of neuroimaging within clinical trials, which until today has proven the right strategy on very fertile ground. But through continuous innovation driven by our scientists, data experts, collaborations with leading researchers and hundreds of thousands of scans / data points processed for our biopharma clients, it has become something far more powerful.
Built by neuroscientists and data scientists, IXI™ combines machine learning and deep learning with deep domain expertise to process complex imaging datasets from neurological trials around the world. IXI™ is now a comprehensive end-to-end AI-enabled neuroimaging platform designed not only to manage imaging data from global clinical trials, but to also analyse that data at scale and generate clinically meaningful insights while reducing variability and increasing reproducibility.
Importantly, IXI™ enables the extraction of precise imaging biomarkers from brain scans helping researchers meet critical endpoints, better understand disease biology, measure treatment effects and make faster, more confident decisions in drug development. It is extremely rewarding for our team to operate at the heart of where decisions around the next generation of solutions in CNS are being made and to shepherd our customers’ assets on a route towards potential regulatory approval.
With a myriad of advanced imaging biomarker algorithms analysing over 150 brain regions across 18 neurological conditions including Alzheimer’s, Parkinson’s, Huntingdon’s, MS and a large number of other rare conditions, IXI™ now supports far more than traditional trial imaging workflows.
Fig 1. IXI - MRI Volumetric Analysis Interphase
So, the new name reflects this broader capability and how far the Platform has come. But also, where it is going next. The latest generation of IXI™ positions IXICO’s technology beyond its traditional imaging CRO remit and recognises the move we made, expanding into diagnostics, mechanistic disease understanding, patient selection/stratification, pre-clinical drug and clinical decision support. A move made by building a very agile and open platform in order for our company to easily collaborate with, integrate into, and partner with systems or organisations working towards the same goal of eradicating specific diseases of the CNS
For our partners across the biopharma and research communities, our mission remains the same: to advance precision medicine through the provision of imaging biomarker insights that help deliver a deeper understanding and ultimately better outcomes for patients living with neurological disease.
We are excited about what comes next as IXI™ continues to evolve and support the development of the of new neurological therapies.
